Envoy Medical, Inc. reported its financial results for the third quarter of 2025, revealing a net revenue of $42,000 for the three months ended September 30, 2025, a decrease of 25% from $56,000 in the same period last year. For the nine months ended September 30, 2025, total revenues were $166,000, down from $183,000 in the prior year. The company experienced an operating loss of $5.7 million for the third quarter, compared to a loss of $5.0 million in the same quarter of 2024. The nine-month operating loss also widened to $15.9 million from $14.7 million year-over-year.
The company’s total assets decreased to $8.2 million as of September 30, 2025, down from $11.5 million at the end of 2024. Current liabilities increased to $9.0 million, up from $7.5 million at the end of the previous fiscal year. The accumulated deficit grew to $305.7 million, reflecting ongoing challenges in achieving profitability. The increase in operating expenses, which totaled $5.8 million for the quarter, was driven by higher general and administrative costs, which rose by 44.5% to $2.4 million, largely due to expenses related to the September 2025 Offering.
Strategically, Envoy Medical has been focusing on the development of its Acclaim® Cochlear Implant, which received FDA Breakthrough Device Designation in 2019. The company recently advanced to the second stage of its pivotal clinical trial for the Acclaim CI, following FDA approval based on preliminary data from the first stage. This trial is critical for the potential commercialization of the Acclaim CI, which is designed to address severe to profound sensorineural hearing loss. The company aims to submit a Premarket Approval (PMA) application to the FDA by late 2027 or early 2028, depending on the trial outcomes.
In terms of operational metrics, Envoy Medical's employee headcount has remained stable, with no significant changes reported. The company continues to manage its cash flow carefully, ending the quarter with $3.6 million in cash, down from $5.5 million at the end of 2024. The company has raised capital through various means, including a registered direct offering in September 2025 that generated $2.5 million, and an additional offering in October 2025 that is expected to provide $4 million in gross proceeds.
Looking ahead, Envoy Medical anticipates continued net losses as it invests in research and development for the Acclaim CI and seeks to establish a market presence. The company is actively monitoring its capital needs and may pursue additional financing options to support its operations and growth initiatives. However, there is uncertainty regarding the timing and success of regulatory approvals, which could significantly impact the company's financial performance and operational strategy.
About Envoy Medical, Inc.
Envoy Medical, Inc. is a pioneering hearing health company dedicated to transforming the treatment of hearing loss through innovative medical technologies. Its flagship product, the Acclaim CI, is a fully implanted cochlear implant designed to enhance the quality of life for individuals with severe to profound hearing loss. Targeting a significant market opportunity of over $80 billion, Envoy is focused on improving patient access and outcomes while navigating regulatory pathways for FDA approval.
About 10-Q Filings
A 10-Q form is an important financial report that public companies in the United States must submit every three months. It gives a clear picture of a company's financial health and recent performance.
Key points about the 10-Q:
- Frequency: Companies file it three times a year, covering the first three quarters. The fourth quarter is covered in a more comprehensive annual report.
-
Content: It includes:
- Financial statements showing the company's current financial position
- Updates from management on the performance and projections of the business
- Information about potential risks the company faces
- Details on how the company is run internally
- Deadline: Must be filed within 40 or 45 days after the quarter ends, depending on the size of the company.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.